Evogene Ltd.

NasdaqCM:EVGN Stock Report

Market Cap: US$11.0m

Evogene Management

Management criteria checks 4/4

We currently do not have sufficient information about the CEO.

Key information

Ofer Haviv

Chief executive officer

US$401.0k

Total compensation

CEO salary percentage97.3%
CEO tenure20.1yrs
CEO ownershipn/a
Management average tenure2.7yrs
Board average tenure6yrs

Recent management updates

Recent updates

Evogene unit files for EPA approval of bio-fungicide LAV.311 for fruit rots

Oct 12

Evogene unit launches 2nd-gen medical cannabis products in Israel

Sep 21

Lavie Bio appoints Guri Oron as CEO

Sep 14

Evogene GAAP EPS of -$0.42 misses by $0.23, revenue of $0.55M beats by $0.33M

Aug 31

Evogene regains compliance with Nasdaq's minimum bid price requirement

Aug 25

Evogen stock rises after unit gets $10M investment from ICL under collaboration agreement

Aug 17

Update On Evogene's Subsidiaries: Biomica, Lavie Bio And AgPlenus

Mar 22

Evogene: Computational Biology Technology Hub; Focus On Canonic (Medical Cannabis)

Mar 03

Evogene's Canonic Begins Selling High THC Cannabis In Israeli Medical Market

Sep 14

Evogene: Bullish With Canonic's Entry Into Israeli Medical Cannabis Markets

Jun 16

Evogene EPS beats by $0.01, beats on revenue

May 26

Evogene unit - Canonic inks cultivation deal for medical cannabis varieties

Dec 23

AgPlenus reaches a 'Lead' Stage in its mode-of-action herbicide program

Dec 15

Evogene: Q3 Update And Upcoming Catalysts

Nov 30

CEO Compensation Analysis

How has Ofer Haviv's remuneration changed compared to Evogene's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$24m

Jun 30 2024n/an/a

-US$20m

Mar 31 2024n/an/a

-US$21m

Dec 31 2023US$401kUS$390k

-US$24m

Sep 30 2023n/an/a

-US$20m

Jun 30 2023n/an/a

-US$23m

Mar 31 2023n/an/a

-US$25m

Dec 31 2022US$464kUS$415k

-US$27m

Sep 30 2022n/an/a

-US$31m

Jun 30 2022n/an/a

-US$32m

Mar 31 2022n/an/a

-US$29m

Dec 31 2021US$530kUS$420k

-US$28m

Sep 30 2021n/an/a

-US$29m

Jun 30 2021n/an/a

-US$26m

Mar 31 2021n/an/a

-US$24m

Dec 31 2020US$592kUS$367k

-US$23m

Sep 30 2020n/an/a

-US$21m

Jun 30 2020n/an/a

-US$21m

Mar 31 2020n/an/a

-US$21m

Dec 31 2019US$538kUS$366k

-US$18m

Sep 30 2019n/an/a

-US$18m

Jun 30 2019n/an/a

-US$18m

Mar 31 2019n/an/a

-US$19m

Dec 31 2018US$517kUS$324k

-US$21m

Compensation vs Market: Ofer's total compensation ($USD401.00K) is below average for companies of similar size in the US market ($USD645.47K).

Compensation vs Earnings: Ofer's compensation has been consistent with company performance over the past year.

CEO

Ofer Haviv (58 yo)

20.1yrs

Tenure

US$401,000

Compensation

Mr. Ofer Haviv, CPA, served as Interim Chief Executive Officer of Lavie Bio Ltd. since January 2023. He has been Chief Executive Officer and President of Evogene Limited since December 2004 and served as i...

Leadership Team

NamePositionTenureCompensationOwnership
Ofer Haviv
CEO & President20.1yrsUS$401.00kno data
Brian Ember
Chief Executive Officer of AgPlenus Ltd3.1yrsUS$456.00kno data
Elran Haber
Chief Executive Officer of Biomica Ltd7yrsUS$339.00k0%
$ 0
Amit Noam
Chief Executive Officer of Lavie Bio Ltd.1.8yrsUS$606.00kno data
Yaron Eldad
Chief Financial Officer2.8yrsno data0%
$ 0
Rachel Gerber
Head of Investor Relations1.6yrsno datano data
Liat Wejgman
Vice President of Human Resources3yrsno datano data
Eyal Ronen
Executive Vice President of Business Development2.6yrsno data0%
$ 0
Yoash Zohar
Chief Executive Officer of Casterra Ag Ltd.less than a yearno datano data
Dan Gelvan
Chief Executive Officer of Ag Plenus Ltd.less than a yearno datano data
Russ Putland
Vice President of Commercial of Lavie Bio Ltd.no datano datano data

2.7yrs

Average Tenure

55yo

Average Age

Experienced Management: EVGN's management team is considered experienced (2.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Dan Falk
Independent Director3.2yrsno data0%
$ 0
Nir Nimrodi
Independent Director2.2yrsno data0%
$ 0
Leon Recanati
Independent Director19.7yrsno data1.23%
$ 136.4k
Sarit Weiss-Firon
Independent Chairperson of the Board8.4yrsno data0%
$ 0
Oded Shoseyov
Independent Director6.2yrsno data0%
$ 0
Adrian Percy
Independent Director5.9yrsno data0%
$ 0

6.0yrs

Average Tenure

63.5yo

Average Age

Experienced Board: EVGN's board of directors are considered experienced (6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 02:38
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Evogene Ltd. is covered by 8 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Scott HenryAlliance Global Partners
Benjamin HaynorAlliance Global Partners
Kristen KluskaCantor Fitzgerald & Co.